The total market capitalization will be around 100 billion won. Neofect was initially valued at 70 billion won earlier this year. A total of 11.7 million shares will be offered. Korea Investment & Securities was selected to manage the listing process. The anticipated valuation at 100 billion won factors in the high potential of the technologies that Neofect includes in its products, including the NeoMano, ComCog and Rapael Smart Glove. Ban said that the number of patients with neurological disorders has been on the rise, a factor that will push up demand for rehabilitation devices. As for technological standards, the government-certified technology assessment agency gave Neofect the highest rating in June before it applied for the listing. Its shortcoming lies in profitability. The company has yet to generate an operating profit. Neofect posted 4.22 billion won in operating losses with 4.45 billion won in revenue in 2017.